Voyager Therapeutics (VYGR) Common Equity (2014 - 2026)
Voyager Therapeutics (VYGR) posted Common Equity of $173.7 million for Q1 2026, down 11.43% sequentially from $196.1 million in Q4 2025, and down 36.32% YoY from $272.7 million in Q1 2025.
Voyager Therapeutics (VYGR) Common Equity (2014 - 2026) Analysis & Trends
Voyager Therapeutics has reported Common Equity for 13 years, with the latest figure at $173.7 million in Q1 2026.
- Quarterly Common Equity fell 36.32% year-over-year to $173.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $173.7 million (down 36.32% YoY) and the FY2025 annual result came in at $196.1 million, down 34.59% from the prior year.
- Common Equity slipped to $173.7 million in Q1 2026 per VYGR's latest filing, from $196.1 million in the prior quarter.
- Over five years, Common Equity peaked at $340.9 million in Q1 2024 and troughed at $59.0 million in Q4 2022.
- A 5-year average of $206.8 million and a median of $217.0 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2023: Common Equity tumbled 45.67% in 2022, then jumped 300.41% in 2023.
- Over 5 years, Common Equity stood at $59.0 million in 2022, then surged by 300.41% to $236.3 million in 2023, then grew by 26.84% to $299.8 million in 2024, then slumped by 34.59% to $196.1 million in 2025, then fell by 11.43% to $173.7 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $173.7 million, $196.1 million, and $219.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Voyager Therapeutics | 201.32 Mn | 84.98 Mn | - | 154.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 154.38 Mn |
| Mar 31, 2026 | 173.67 Mn |
| Dec 31, 2025 | 196.08 Mn |
| Sep 30, 2025 | 219.83 Mn |
| Jun 30, 2025 | 243.94 Mn |
| Mar 31, 2025 | 272.70 Mn |
| Dec 31, 2024 | 299.76 Mn |
| Sep 30, 2024 | 330.31 Mn |
| Jun 30, 2024 | 335.42 Mn |
| Mar 31, 2024 | 340.89 Mn |
| Dec 31, 2023 | 236.32 Mn |
| Sep 30, 2023 | 176.22 Mn |
| Jun 30, 2023 | 199.03 Mn |
| Mar 31, 2023 | 216.96 Mn |
| Dec 31, 2022 | 59.02 Mn |
| Sep 30, 2022 | 79.82 Mn |
| Jun 30, 2022 | 60.05 Mn |
| Mar 31, 2022 | 75.93 Mn |
| Dec 31, 2021 | 95.06 Mn |
| Sep 30, 2021 | 87.42 Mn |